Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Stereotactic body radiotherapy compared to conventionally fractionated radiotherapy for locally advanced or oligometastatic pancreatic cancer.
Authors
Ofri Mizrahi
Hadassah Hebrew University Medical Center, Jerusalem, Israel
Ofri Mizrahi , Tal Falick Michaeli , Ayala Hubert , Marc R. Wygoda , Philip Blumenfeld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 677)
DOI
10.1200/JCO.2024.42.3_suppl.677
Abstract #
677
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2019 Gastrointestinal Cancers Symposium
Comparison of concurrent chemoradiation with stereotactic body radiation therapy versus conventionally fractionated radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.
First Author: Sung Jun Ma
Poster
2018 Gastrointestinal Cancers Symposium
Effect of stereotactic radiation (SBRT) on survival in a preclinical model of spontaneous pancreatic cancer with induction gemcitabine/nab-paclitaxel.
First Author: Cullen M. Taniguchi
Poster
2014 Gastrointestinal Cancers Symposium
Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma.
First Author: Marie Kate Gurka